Vaccine makers gain amid growing concerns around bird flu

CureVac NV

07/01/2025 20:51

(Updates prices to late afternoon)
    ** Shares of vaccine maker Moderna  MRNA.O  rise ~13% to
$48.16, eyeing highest daily percentage gain since May 24,
Novavax  NVAX.O  rises ~10% to $10.74, and U.S.-listed shares of
Germany's CureVac N.V  CVAC.O  rise 5.7% to ~$4.70 
    ** NVAX, MNRA both on track for 5th straight daily gain
    ** Brookline Capital Markets analyst Leah Cann said
increasing concerns around bird flu could be contributing to the
vaccine makers' recent share gains 
    ** The U.S. government in July awarded $176 million to MRNA
to complete late-stage development and testing of a pre-pandemic
mRNA-based bird flu vaccine 
    ** The U.S. on Monday reported its first human death from
H5N1 bird flu in Louisiana 
    ** Moderna lost 58.2% of its value in 2024, marking its
third straight year of losses, while NVAX snapped a two-year
losing streak gaining ~68%

 (Reporting by Mariam Sunny in Bengaluru, Sinéad Care in New
York)
 ((Mariam.ESunny@thomsonreuters.com;
sinead.carew@thomsonreuters.com;))